High Tech Pharm KRX:106190KOSDAQ
하이텍팜 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked2since Sep 11
In Q2 2026, High Tech Pharm reported revenue of ₩23.4bn, up 1.6% year on year, and operating profit of ₩6.3bn. High Tech Pharm (하이텍팜) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Profit +50% Op. margin 20%+ Screener
High Tech Pharm quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩23.4bn | +1.6% | ₩6.3bn margin 26.9% | ₩5.2bn |
| Q1 2026 | ₩14.1bn | -7.4% | −₩1.1bn margin −7.8% | −₩267m |
| Q4 2025 derived | ₩14.0bn | -27.8% | ₩3.2bn margin 22.6% | ₩3.2bn |
| Q3 2025 | ₩17.9bn | +5.6% | ₩3.9bn margin 21.9% | ₩3.8bn |
| Q2 2025 | ₩23.0bn | +4.9% | ₩3.2bn margin 14.0% | ₩2.3bn |
| Q1 2025 | ₩15.3bn | -20.5% | ₩2.6bn margin 16.8% | ₩2.2bn |
| Q4 2024 derived | ₩19.5bn | -17.2% | ₩2.8bn margin 14.4% | ₩3.7bn |
| Q3 2024 | ₩16.9bn | -10.3% | ₩3.7bn margin 22.0% | ₩2.4bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
High Tech Pharm top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest High Tech Pharm news Korean headlines
-
Major하이텍팜, '에르타페넴 원료 사용 완제의약품' 스위스 시판허가 획득
1 more on this story · 1 outlets
- 하이텍팜 원료 사용 항생제, 스위스 시판허가 획득이데일리 · Oct 2 09:48